Symbolbild · KI-generiert
Neupath Health Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
NeuPath operates one of Canada's largest networks of community-based, multidisciplinary medical facilities focused on the assessment and treatment of chronic pain, musculoskeletal/back pain, sports medicine and other pain medical services. NeuPath provides improved access to care and outcomes for patients by leveraging best-in-class treatments and delivering patient-centered multidisciplinary care. Working within Canada's publicly funded healthcare system, NeuPath delivers insured medical services to help extend the appropriate care from hospitals into the community, which are complemented by select non-insured procedures to provide a comprehensive and coordinated treatment for patients.
Company description as published by the issuer via TMX Money.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Neupath Health Inc. | NPTH | TSXV | 25 Mio. USD |
| iAnthus Capital Holdings Inc. | IAN | CSE | 25 Mio. USD |
| Cheelcare Inc. | CHER | TSXV | 25 Mio. USD |
| C21 Investments Inc. | CXXI | CSE | 25 Mio. USD |
| MariMed Inc. | MRMD | CSE | 26 Mio. USD |
| Diagnos Inc. | ADK | TSXV | 24 Mio. USD |
| Medicenna Therapeutics Corp. | MDNA | TSX | 24 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.